Sympathetic Overdrive and Role of Beta-blockers in Various Forms of Heart Failure: A Consensus Statement from India.

• DOI: 10.59556/japi.72.0740
• Publication Date: 2024-11-01
• Authors: H K Chopra; Gurpreet Singh Wa...; Tiny Nair; C K Ponde; Navin C. Nanda; Jagat Narula; Saumitra Ray; K Venugopal; S. S. Iyengar; Ravi R. Kasliwal; Praveen Chandra; Sunil Prakash; Sandeep Bansal; D S Rana; Prafulla Kerkar; Arup Dasbiswas; JPS Sawhney; S Shanmungasundram; Viveka Kumar; I B Vijayalakshmi; A K Pancholia; Atul Sharma; Aditya Kapoor; H.S. Isser; Vishal Rastogi; Yashita Arora; Ashok K Omar; Sunil Sathe; Rajeeve Rajput; D Prabhakar; G. Justin Paul; Priya Jagia; Poonam Malhotra; G Suryaprakash; Vinod Kumar Mittal; Manish Jagia; Jabir Abdullakutty; S S Mishra; S N Routray; Ajay Sinha; Mohan Bhargava; Kiran Mahmood; Mona Bhatia; Pramila Kalra; V K Katyal; Rohit Tandon; Rahul Grover; Abhinav Chhabra; N R Shastry
• Keywords: Statement (logic); BETA (programming language)

In heart failure, sympathetic overdrive is evidenced by norepinephrine spillover, receptor level changes, etc. Beta-blockers continue to be the cornerstone of treatment in patients with chronic failure due their ability counteract overdrive. Extensive clinical research has demonstrated that long-term beta-blocker metoprolol succinate, carvedilol, or bisoprolol enhances left ventricular function and reverses remodeling, decreases hospitalization risk, increases survival. The aim this consensus paper identify patient profiles, initiation up-titration beta-blockers benefits chirally pure failure. This expert will ensure precise implementation as a part guideline-directed medical therapy.